CSBR (Champions Oncology) Treasury Stock: $-0.71 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSBR Champions Oncology Inc CSBR
61 GF Score
Price $5.78
GF Value $6.66
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Treasury Stock?

Champions Oncology CSBR +2.12% 61 Treasury Stock is $-0.71 Mil as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 61/100 and a GF Value™ of $6.66 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Champions Oncology's treasury stock for the quarter that ended in Jan. 2026 was $-0.71 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Champions Oncology Treasury Stock Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Treasury Stock Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.07 -0.71 -0.71

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.71 -0.71 -0.71 -0.71 -0.71
CSBR
61GF Score
Champions Oncology Inc CSBR
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $-0.71 Mil mean?
Champions Oncology (CSBR) has a Treasury Stock of $-0.71 Mil as of Jan. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Champions Oncology and its competitors.
Is Champions Oncology's Treasury Stock too high?
Champions Oncology's current Treasury Stock is $-0.71 Mil. Overall, Champions Oncology has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Treasury Stock compare to SEER and RLYB?
Champions Oncology's Treasury Stock of $-0.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Champions Oncology and its competitors. Champions Oncology's current Treasury Stock is $-0.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.66, compared to a current price of $5.78 — trading 13.2% below its estimated fair value. The current Treasury Stock is $-0.71 Mil. Champions Oncology's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Treasury Stock is $-0.71 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $5.78 is trading 13.2% below its estimated GF Value™ of $6.66. GuruFocus considers Champions Oncology to be Modestly Undervalued.

Key valuation signals for CSBR:

  • Treasury Stock: $-0.71 Mil
  • GF Value™: $6.66 vs. price of $5.78 (13.2% below fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
61GF Score

Get the complete analysis for CSBR

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.78
Price
$6.66
GF Value